IEV versus ESHAP for Treatment of the Patients with Relapsed/Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran: A Cost-Effectiveness Analysis

Mostafa Habibian^1* and Mehdi Dehghani²

¹Master of Health Economics, School of Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran

²Hematology and oncology ward, hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

^*Corresponding Author: Mostafa Habibian, Master of Health Economics, School of Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran, Tel: 00989013766363 Email: